Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
E. Seregni, A. Chiti, E. Bombardieri.
Radionuclide imaging of neuroendocrine tumors: biological basis and diagnostic results.
Eur J Nucl Med, 25 (1998), pp. 639-658
[2.]
J.O. Olsen, R.V. Pozderac, G. Hinkle, T. Hill, T.M. O'Dorisio, W.J. Schirmer, et al.
Somatostatin receptor imaging of neuroendocrine tumors with indium-111 pentetreotide (OctreoScan).
Semin Nucl Med, 25 (1995), pp. 251-261
[3.]
B.A. Scott, R.A. Gatenby.
Imaging advances in the diagnosis of endocrine neoplasia.
Curr Opin Oncol, 10 (1998), pp. 37-42
[4.]
J.J. Mateos, F. Pons, D. Fuster, S. Vidal-Sicart, F. Lomeña, R. Herranz.
111In-pentetreótida en el estudio de tumores que expresan receptores para la somatostatina.
Rev Esp Med Nuclear, 18 (1999), pp. 325-330
[5.]
E.P. Krenning, D.J. Kwekkeboom, S. Pauwels, L. Kvols, J.C. Reubi.
Somatostatin receptor scintigraphy.
Nuclear Medicine Annual 1995, pp. 1-50
[6.]
R. Astorga.
Análogo de la somatostatina: perspectivas actuales y futuras.
Med Clin (Barc), 93 (1989), pp. 508-515
[7.]
D. Blok, R.I.J. Feitsma, P. Vermeij, E.J.K. Pauwels.
Peptide radiopharmaceuticals in nuclear medicine.
Eur J Nucl Med, 26 (1999), pp. 1511-1519
[8.]
E.K.J. Pauwels, V.R. McCready, J.H.M.B. Stoot, D.F.P. van Deurzen.
The mechanism of accumulation of tumour-localising radiopharmaceuticals.
Eur J Nucl Med, 25 (1998), pp. 277-305
[9.]
T.M. Behr, M. Béhé, W. Becker.
Diagnostic applications of radiolabeled peptides in nuclear endocrinology.
Q J Nucl Med, 43 (1999), pp. 268-280
[10.]
J. Banzo, M.D. Abós, E. Prats, F. García, P. Razola.
La gammagrafía de receptores de somatostatina en el diagnóstico y estadificación de los tumores neuroendocrinos del aparato digestivo y páncreas.
Rev Esp Med Nuclear, 19 (2000), pp. 225-239
[11.]
S.W.J. Lamberts, W.H. Bakker, J.C. Reubi, E.P. Krenning.
Somatostatin-receptor imaging in the localization of endocrine tumors.
N Engl J Med, 323 (1990), pp. 1246-1249
[12.]
L.K. Kvols, M.L. Brown, M.K. O'Connor, J.C. Hung, R.J. Hayostek, J.C. Reubi, et al.
Evaluation of a radiolabeled somatostatin analog (I-123 octreotide) in the detection and localization of carcinoid and islet cell tumors.
Radiology, 187 (1993), pp. 129-133
[13.]
E.P. Krenning, D.J. Kwekkeboom, W.H. Bakker, W.A.P. Breeman, P.P.M. Kooij, H.Y. Oei, et al.
Somatostatin receptor scintigraphy with [[1]In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients.
Eur J Nucl Med, 20 (1993), pp. 716-731
[14.]
A.J. Fischman, J.W. Babich.
Radiolabeled peptides: a new class of imaging agents.
Nuclear Medicine Annual 1997, pp. 103-131
[15.]
E.P. Krenning, W.H. Bakker, P.P.M. Kooij, W.A.P. Breeman, H.Y. Oei, M. de Jong, et al.
Somatostatin receptor scintigraphy with indium-111- DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide.
J Nucl Med, 33 (1992), pp. 652-658
[16.]
D. Kwekkeboom, E.P. Krenning, M. de Jong.
Peptide receptor imaging and therapy.
J Nucl Med, 41 (2000), pp. 1704-1713
[17.]
Información técnica.
Equipo para la preparación de Indio (In[1]) Pentetreótida (OctreoScan®).
Mallinckrodt Medical, junio, (1995),
[18.]
M.G. Stabin, P.P.M. Kooij, W.H. Bakker, T. Inone, K. Endo, J. Coveney, et al.
Radiation dosimetry for indium-111-pentetreotide.
J Nucl Med, 38 (1997), pp. 1919-1922
[19.]
G.A. Wiseman.
111In-Pentetreotide scan.
The Mayo Clinic Manual of Nuclear Medicine, pp. 265-269
[20.]
U. Dörr, U. Räth, M.L. Sautter-Bihl, G. Guzman, D. Bach, H.J. Adrian, et al.
Improved visualization of carcinoid liver metastases by indium-111 pentetreotide scintigraphy following treatment with cold somatostatin analogue.
Eur J Nucl Med, 20 (1993), pp. 431-433
[21.]
P.C. Buetow, D.L. Miller, T.V. Parrino, J.L. Buck.
Islet cell tumors of the pancreas: clinical, radiologic, and pathologic correlation in diagnosis and localization (From the archives of the AFIP).
RadioGraphics, 17 (1997), pp. 453-472
[22.]
R.T. Jensen.
Carcinoid and pancreatic endocrine tumors: recent advances in molecular pathogenesis, localization, and treatment.
Curr Opin Oncol, 12 (2000), pp. 368-377
[24.]
M.H. Kulke, R.J. Mayer.
Medical progress: Carcinoid tumors.
N Engl J Med, 340 (1999),
[25.]
M. Delgado, P. Razola, M.D. Abós, F. García, E. Prats, J. Banzo.
Gammagrafía con receptores de somatostatina en un insulinoma metastásico.
Rev Esp Med Nuclear, 19 (2000), pp. 505-506
[26.]
E. De Kervilier, G. Cadiot, R. Lebtahi, M. Faraggi, D. Le Gudulec, M. Mignon, et al.
Somatostatin receptor scintigraphy in forty-eight patients with the Zollinger-Ellison syndrome.
Eur J Nucl Med, 21 (1994), pp. 1191-1197
[27.]
O. Schillaci, F. Scopinaro, S. Angeletti, R. Tavolaro, R. Danielli, B. Annibale, et al.
SPECT improves accuracy of somatostatin receptor scintigraphy in abdominal carcinoid tumors.
J Nucl Med, 37 (1996), pp. 1452-1456
[28.]
V.D. Corleto, F. Scopinaro, S. Angeletti, A. Materia, N. Basso, E. Polettini, et al.
Somatostatin receptor localization of pancreatic endocrine tumors.
World J Surg, 20 (1996), pp. 241-244
[29.]
O. Schillaci, R. Massa, F. Scopinaro.
111In-pentetreotide scintigraphy in the detection of insulinomas: importance of SPECT imaging.
J Nucl Med, 41 (2000), pp. 459-462
[30.]
A. Chiti, S. Fanti, G. Savelli, A. Romeo, B. Bellanova, M. Rodari, et al.
Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours.
Eur J Nucl Med, 25 (1998), pp. 1396-1403
[31.]
D. Kwekkeboom, E.P. Krenning, W.H. Bakker, H.Y. Oei, P.P.M. Kooij, S.W.J. Lamberts.
Somatostatin analogue scintigraphy in carcinoid tumors.
Eur J Nucl Med, 20 (1993), pp. 283-292
[32.]
O. Kisker, R.J. Weinel, J. Geks, F. Zacara, K. Joseph, M. Rothmund.
Value of somatostatin receptor scintigraphy for preoperative localization of carcinoids.
World J Surg, 20 (1996), pp. 162-167
[33.]
F. Gibril, J.C. Reynolds, I.A. Lubensky, P.K. Roy, P.L. Peghini, J.L. Doppman, et al.
Ability of somatostatin receptor scintigraphy to identify patients with gastric carcinoids: a prospective study.
J Nucl Med, 41 (2000), pp. 1646-1656
[34.]
J. Banzo, M.D. Abós, E. Prats, M. Delgado, P. Razola, S. García, et al.
La gammagrafía de receptores de somatostatina en el tumor carcinoide.
Rev Esp Med Nuclear, 20 (2001), pp. 11-18
[35.]
C.A. Hoefnagel.
Metaiodobenzylguanidine and somatostatin in oncology: role in the management of neural crest tumours.
Eur J Nucl Med, 21 (1994), pp. 561-581
[36.]
B. Shapiro, L.M. Fig, M.D. Gross, B.L. Shulkin, J.C. Sisson.
Neuroendocrine tumors.
Nuclear oncology, pp. 3-31
[37.]
G. Kaltsas, M. Korbonits, E. Heintz, J.J. Mukherjee, P.J. Jenkins, S.L. Chew, et al.
Comparison of somatostatin analog and metaiodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors.
J Clin Endocrinol Metab, 86 (2001), pp. 895-902
[38.]
S. Adams, R. Baum, T. Rink, P.M. Schumm-Dräger, K.H. Usadel.
Hör G. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumors.
Eur J Nucl Med, 25 (1998), pp. 79-83
[39.]
J. Erasmus, H.P. McAdams, E.F. Patz, R.E. Coleman, V. Ahuja, P.C. Goodman.
Evaluation of primary pulmonary carcinoid tumors using FDG PET.
AJR, 170 (1998), pp. 1369-1373
[40.]
C. Le Rest, J.B. Bomanji, D.C. Costa, C.E. Townsend, D. Visvikis, P.J. Ell.
Functional imaging of malignant paragangliomas and carcinoid tumours.
Eur J Nucl Med, 28 (2001), pp. 478-482
[41.]
B. Eriksson, M. Bergström, A. Lilja, H. Ahlström, B. Långström, K.E. Öberg.
PET imaging in endocrine tumors.
Diagnostic nuclear medicine (3rd ed.), pp. 1067-1073
[42.]
F. Gibril, J.C. Reynolds, J.L. Doppman, C.C. Chen, D.J. Venzon, B. Termanini, et al.
Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas.
Ann Intern Med, 125 (1996), pp. 26-34
[43.]
G. Cadiot, R. Lebtahi, L. Sarda, G. Bonnaud, J.P. Marmuse, Vissuzaine, et al.
Preoperative detection of duodenal gastrinomas and peripancreatic lymph nodes by somatostatin receptor scintigraphy.
Gastroenterology, 111 (1996), pp. 845-854
[44.]
R. Lebtahi, G. Cadiot, L. Sarda, D. Daou, M. Faraggi, Y. Petegnief, et al.
Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors.
J Nucl Med, 38 (1997), pp. 853-858
[45.]
D.J. Kwekkeboom, S.W.J. Lamberts, J.D.F. Habbema, E.P. Krenning.
Costeffectiveness analysis of somatostatin scintigraphy.
J Nucl Med, 37 (1996), pp. 886-892
[46.]
R.S. Woodward, M.A. Schnitzler, L.S. Kvols.
Reduced uncertainty as a diagnostic benefit: an initial assessment of somatostatin receptor scintigraphy's value in detecting distant metastases of carcinoid liver tumors.
Health Econ, 7 (1998), pp. 149-160
[47.]
F. Jamar, R. Fiasse, N. Leners, S. Pauwels.
Somatostatin receptor imaging with indium-111-pentetreotride in gastroenteropancreatic neuroendocrine tumors: safety, efficacy and impact on patient management.
J Nucl Med, 36 (1995), pp. 542-549
[48.]
B. Termanini, F. Gibril, J.C. Reynolds, J.L. Doppman, C.C. Chen, C.A. Stewart, et al.
Value of somatostatin receptor scintigraphy: a prospective study in gastrinoma of its effect on clinical management.
Gastroenterology, 112 (1997), pp. 335-347
[49.]
R. Lebtahi, G. Cadiot, N. Delahaye, R. Genin, M.C. Daou D Peker, et al.
Detection of bone metastases in patients with endocrine gastroenteropancreatic tumors: bone scintigraphy compared with somatostatin receptor scintigraphy.
J Nucl Med, 40 (1999), pp. 1602-1608
[50.]
F. Gibril, J.L. Doppman, J.C. Reynolds, C.C. Chen, V.E. Sutliff, J. Serrano, et al.
Bone metastases in patients with gastrinomas: a prospective study of bone scanning, somatostatin receptor scanning, and magnetic resonance image in their detection, frecuency, location, and effect of their detection on management.
J Clin Oncol, 16 (1998), pp. 1040-1053
[51.]
M. Cortés, J. Mora, A. Benítez, Y. Ricart, M.J. González, M. Castell, et al.
Metástasis ósea de gastrinoma sin afectación hepática. Utilidad de la gammagrafía con 111In-pentetreotide.
Rev Esp Med Nuclear, 20 (2001), pp. 23-26
[52.]
F. Gibril, J.C. Reynolds, C.C. Chen, F. Yu, S.U. Goebel, J. Serrano, et al.
Specificity of somatostatin receptor scintigraphy: a prospective study and effects of false-positive localizations on management in patients with gastrinomas.
J Nucl Med, 40 (1999), pp. 539-553
[53.]
J.D. Horn, B.M. Gordon, L. Gordon, K.M. Spicer.
Octreotide uptake in head and neck.
Semin Nucl Med, 27 (1997), pp. 79-81
[54.]
O. Nilsson, L. Kölby, B. Wängberg, A. Wigander, H. Billig, L. William-Olson, et al.
Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours.
Br J Cancer, 77 (1998), pp. 632-637
[55.]
B. Carnaille, M. Nocaudie, F. Pattou, D. Huglo, M. Deveaux, X. Marchandise, et al.
Scintiscans and carcinoid tumors.
Surgery, 116 (1994), pp. 1118-1122
[56.]
D.J. Kwekkeboom, E.P. Krenning.
Somatostatin receptor scintigraphy in patients with carcinoid tumors.
World J Surg, 20 (1996), pp. 157-161
[57.]
I.M. Modlin, L.H. Tang.
Approaches to the diagnosis of gut neuroendocrine tumors: the last word (today).
Gastroenterology, 112 (1997), pp. 583-590
[58.]
I.R. Francis, M. Korobkin.
Pheochromocytoma.
Radiol Clin North Am, 34 (1996), pp. 1101-1112
[59.]
A.B. Rao, K.K. Koeller, C.F. Adair.
Paragangliomas of the head and neck: radiologic-pathologic correlation (from the archives of the AFIP).
RadioGraphics, 19 (1999), pp. 1605-1632
[60.]
J.C. Sisson, B.L. Shulkin.
Nuclear medicine imaging of pheochromocytoma and neuroblastoma.
Q J Nucl Med, 43 (1999), pp. 217-223
[61.]
R.L. Cirillo, W.F. Benett, K.M. Vitellas, A.G. Poulos, J.G. Bova.
Pathology of the adrenal gland: imaging features.
AJR, 170 (1998), pp. 429-435
[62.]
L. Troncone, V. Rufini.
Nuclear medicine therapy of pheochromocytoma and paraganglioma.
Q J Nucl Med, 43 (1999), pp. 344-355
[63.]
F. Tenenbaum, J. Lumbroso, M. Schlumberger, A. Mure, P.F. Plouin, B. Caillou, et al.
Comparison of radiolabeled octreotide and meta-iodobenzylguanidine (MIBG) scintigraphy in malignant pheochromocytoma.
J Nucl Med, 36 (1995), pp. 1-6
[64.]
D. Kopf, A. Bockisch, H. Steinert, K. Hahn, J. Beyer, H.P.H. Neumann, et al.
Octreotide scintigraphy and catecholamine response to an octreotide challenge in malignant pheochromocytoma.
Clin Endocrinol, 46 (1997), pp. 39-44
[65.]
D.J. Kwekkeboom, H. van Urk, B.K.H. Pauw, S.W.J. Lamberts, P.P.M. Kooij, R.P.L.M. Hoogma, et al.
Octreotide scintigraphy for the detection of paragangliomas.
J Nucl Med, 34 (1993), pp. 873-878
[66.]
D. Myssiorek, C.J. Palestro.
111Indium pentetreotide scan detection of familial paragangliomas.
Laryngoscope, 108 (1998), pp. 228-231
[67.]
M.A. Muros, J.M. Llamas-Elvira, A. Rodríguez, A. Ramírez, M. Gómez, M.A. Arráez, et al.
111In-pentetreotide scintigraphy is superior to 123IMIBG scintigraphy in the diagnosis and location of chemodectoma.
Nucl Med Commun, 19 (1998), pp. 735-742
[68.]
B.L. Shulkin, N.W. Thompson, B. Shapiro, I.R. Francis, J.C. Sisson.
Pheochromocytomas: imaging with 2-[fluorine-18]fluoro-2-deoxy-D-glucose PET.
Radiology, 212 (1999), pp. 35-41
[69.]
D.J. Macfarlane, B.L. Shulkin, K. Murphy, G.T. Wolf.
FDG PET imaging of paragangliomas of the neck: comparison with MIBG SPET.
Eur J Nucl Med, 22 (1995), pp. 1347-1350
[71.]
F. Grünwald, B. Briele, H.J. Biersack.
Non-131I-scintigraphy in the treatment and follow-up of thyroid cancer Single-photon-emitters or FDGPET?.
Q J Nucl Med, 43 (1999), pp. 195-206
[72.]
E. Baudin, J. Lumbroso, M. Schlumberger, J. Leclere, F. Giammarile, P. Gardet, et al.
Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma.
J Nucl Med, 37 (1996), pp. 912-916
[73.]
S. Adams, R.P. Baum, A. Hertel, P.M. Schumm-Draeger, K.H. Usadel.
Hör G. Comparison of metabolic and receptor imaging in recurrent medullary thyroid carcinoma with histopathological findings.
Eur J Nucl Med, 25 (1998), pp. 1277-1283
[74.]
T. Behr, S. Gratz, P.M. Markus, R.M. Dunn, M. Hüfner, A. Schauer, et al.
Anti-carcinoembryonic antigen antibodies versus somatostatin analogs in the detection of metastatic medullary thyroid carcinoma Are carcinoembryonic antigen and somatostatin receptor expression prognostic factors?.
Cancer, 80 (1997), pp. 2436-2457
[75.]
C. MaríC, A. Flotats, L. Bernà, M. Estorch, A. Catafau, I. Carrió.
[1]In-pentetreotida en el diagnóstico de localización de la recidiva del carcinoma medular de tiroides.
Rev Esp Med Nuclear, 16 (1997), pp. 316-320
[76.]
L. BernàL, A. Chico, X. Matías-Guiu, E. Mato, A. Catafau, C. Alonso, et al.
Use of somatostatin analogue scintigraphy in the localization of recurrent medullary thyroid carcinoma.
Eur J Nucl Med, 25 (1998), pp. 1482-1488
[77.]
T.M. Behr, S. Gratz, P.M. Markus, R.M. Dunn, M. Hüfner, H. Becker, et al.
Enhaced bilateral somatostatin receptor expression in mediastinal lymph nodes ("chimney sign™) in occult metastatic medullary thyroid cancer: a typical site of tumour manifestation?.
Eur J Nucl Med, 24 (1997), pp. 184-191
[78.]
S.A. Gulec, F.L. Moffat, R.G. Carroll.
The expanding clinical role for intraoperative gamma probes.
Nuclear Medicine Annual 1997, pp. 209-237
[79.]
D. Krag, F. Moffat.
Nuclear medicine and the surgeon.
Lancet, 354 (1999), pp. 1019-1022
[80.]
U. Öhrvall, J.E. Westlin, S. Nilsson, C. Juhlin, J. Rastad, H. Lundqvist, et al.
Intraoperative detection reveals abdominal endocrine tumors more efficiently than somatostatin receptor scintigraphy.
Cancer, 80 (1997), pp. 2490-2494
[81.]
W.A. Waddington, A.G. Kettle, R.M. Heddle, A.J. Coakley.
Intraoperative localization of recurrent medullary carcinoma of the thyroid using indium-[1] pentetreotide and nuclear surgical probe.
Eur J Nucl Med, 21 (1994), pp. 363-364
[82.]
J.F. Chatal, C.A. Hoefnagel.
Radionuclide therapy.
Lancet, 354 (1999), pp. 931-935
[83.]
M. De Jong, W.A.P. Breeman, H.F. Bernard, P.P.M. Kooij, G.D. Slooter, C.H.J. Van Eijck, et al.
Therapy of neuroendocrine tumors with radiolabeled somatostatin-analogues.
Q J Nucl Med, 43 (1999), pp. 356-366
[84.]
E.T. Janson, J.E. Westlin, U. Öhrvall, K. Öberg, A. Lukinius.
Nuclear localization of 111In after intravenous injection of [111In-DTPA-D-Phe1]- octreotide in patients with neuroendocrine tumors.
J Nucl Med, 41 (2000), pp. 1514-1518
[85.]
M.E. Caplin, W. Mielcarek, J.R. Buscombe, A.L. Jones, P.L. Croasdale, M.S. Cooper, et al.
Toxicity of high-activity 111In-Octreotide therapy in patients with disseminated neuroendocrine tumours.
Nucl Med Commun, 21 (2000), pp. 97-102
[86.]
M. De Jong, W.H. Bakker, E.P. Krenning, W.A.P. Breeman, M.E. van der Pluijm, B.F. Bernard, et al.
Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,D-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy.
Eur J Nucl Med, 24 (1997), pp. 368-371
[87.]
A. Otte, E. Jermann, M. Behe, M. Goetze, H.C. Bucher, H.W. Roser, et al.
DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy.
Eur J Nucl Med, 24 (1997), pp. 792-795
Copyright © 2002. Sociedad Española de Endocrinología y Nutrición
